October 24, interim report
July – September 2024
Alligator hosted a webinar on Thursday, October 24, at 3 p.m. CEST for investors, analysts and media, where CEO Søren Bregenholt and CFO Johan Giléus presented and commented on the Q3 interim report, which was followed by a Q&A session.
The call was held in English, and can be requested below.
LATEST NEWS
Last day of trading in warrants series TO 9 in Alligator Bioscience AB is 13 December 2024
13 December 2024 is the last day of trading in warrants series TO 9 in Alligator Bioscience AB (“Alligator Bioscience” or the &# …
Alligator Bioscience publishes financial calendar for 2025
Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX), hereby publishes its financial calendar for 2025: Extraordinary General …
Alligator Announces First Patient Dosed in Shanghai Henlius Biotech, Inc. Phase 3 Clinical Trial
Lund, Sweden, November 27, 2024 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Company was notified that th …